Nonlinear pharmacokinetics of efavirenz (DMP-266), a potent HIV-1 reverse transcriptase inhibitor, in rats and monkeys

Drug Metabolism and Disposition

Volumn 27, Issue 1, 1999, Pages 41-45

  Balani, Suresh K ^a   Kauffman, Laura R ^a   Deluna, Florencia A ^a   Lin, Jiunn H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG METABOLISM; DRUG SAFETY; MALE; MONKEY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; STOMACH EMPTYING;

ANIMALS; ANTI-HIV AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; HALF-LIFE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; MACACA MULATTA; MALE; METABOLIC CLEARANCE RATE; OXAZINES; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE INHIBITORS;

ANIMALIA; EMESIS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0033047282     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Amir I, Anwar N, Baraona E and Lieber CS (1996) Ranitidine increases the bioavailability of imbibed alcohol by accelerating gastric emptying. Life Sci 58:511-518.
2. Asai T, Mapleson WW and Power I (1997) Differential effects of clonidine and dexmedetomidine on gastric emptying and gastrointestinal transit in the rat. Br J Anaesth 78:301-307.
3. Bodemar G, Norlander B, Fransson L and Walan A (1979) The absorption of cimetidine before and during maintenance treatment with cimetidine and influence of a meal on the absorption of cimetidine studies in patients with peptic ulcer disease. Br J Clin Pharmacol 7:23-31.
4. Clements JA, Heading RC, Nimmo WS and Prescott LF (1978) Kinetics of acetaminophen absorption and gastric emptying in man. Clin Pharmacol Ther 24:420-431.
5. Cohen J, Pennisi E, Weiss RA, Richman DD and Bloom BR (1996) The new face of AIDS. Special report. Science 272:1876-1890.
6. Cortot A, Phillips SF and Malagelada JR (1975) Gastric emptying of lipids after ingestion of solid-liquid meal in humans. Gastroenterology 80:922-927.
7. Erickson JW and Burt SK (1996) Structural mechanism of HIV drug resistance. Annu Rev Pharmacol Toxicol 36:545-571.
8. Fiske WD, Finan WL, Robinson CA, Connell JM and Kornhauser DM (1997a) Pharmacokinetics, safety and tolerability of single escalating doses of efavirenz (DMP 266). an HIV-1 non-nucleoside reverse transcriptase inhibitor, in healthy volunteers. Presented at the AAPS Meeting, Boston, MA, November 2-6, 1997.
9. Fiske WD, Mayers D, Wagner K, Riddler S, Drusano G. Stein D, Bach M, Havlir D and Kahn J (1997b) Pharmacokinetics of DMP 266 and indinavir multiple oral doses in HIV-1 infected individuals. Presented at Retroviruses, 4th Annual Conference, Washington, DC, January 22-26 (Abstract 568).
10. Gibaldi M (ed.) (1991) Biopharmaceutics and Clinical Pharmacokinetics,pp 29-36, Lea & Febiger, Philadelphia.
11. Gulick R (1996) Third National Conference on Human Retroviruses and Related Infections, Washington, DC, January 29 (Abstract), p 162.
12. Kahn J, Mayers D, Riddler S, Bach M, Stein D, Havlir D and Ruiz N (1997) Long-term anti-HIV activity and tolerability of DMP 266 in combination with indinavir (IDV). Presented at Clinical Microbiology and Infectious Diseases, 8th European Congress, Lausanne, Switzerland, May 25-28.
13. 3H-labelled polyethylene glycol 4000 as non-absorbable water phase markers in the human. Scand J Gastroentrol 10:105-108.
14. Kwan KC (1997) Oral bioavailability and first-pass effects. Drug Metab Disp 25:1329-1336.
15. Leesman GD, Sinko PJ and Amidon GL (1988) Simulation of oral drug absorption. Gastric emptying and gastrointestinal motility, in Pharmacokinetics (Welling PG and Tse FLS eds) pp 267-284, Marcel Dekker, Inc., New York.
16. Levy JA (ed) (1994) HIV and the Pathogenesis of AIDS pp 1-33, A.S.M. Press, Washington, DC.
17. Lin JH (1994) Dose-dependent pharmacokinetics: Experimental observation and theoretical considerations. Biopharm Drug Disp 15:1-31.
18. Oberle JRL and Amidon GL (1987) The influence of variable gastric emptying and intestinal transit rates on the plasma levels of cimetidine. An explanation for the double peak phenomenon. J Pharm Biopharm 15:529-544.
19. Ohba M, Ohnishi N, Komada F, Iwakawa S and Okumura K (1996) Effect of clarithromycin on the bioavailability of cyclosporin in rats. Biol Pharm Bull 19:733-737.
20. Parlesak A, Bode JC and Bode C (1994) Parallel determination of gut permeability in man with M(r) 400, M(r) 1500, M(r) 4000 and M(r) 10,000 polyethylene glycol. Eur J Clin Chem Clin Biochem 32:813-820.
21. Rasmussen L, Qvist N, Oster JE, Rehfeld JF, Holst JJ and Pedersen SA (1997) A double-blind placebo-controlled study on the effects of omeprazole on gut hormone secretion and gastric emptying rates. Scand J Gastroenterol 32:900-905.
22. Rocci ML and Jusko WJ (1983) LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed 16:203-216.
23. Ruiz N, Riddler S, Mayers D, Wagner K, Bach M. Havlir D, Stein D, Kahn J and Labriola D (1997) A double-blind pilot study to evaluate the antiretroviral activity, tolerability of DMP 266 alone and in combination with indinavir. Presented at "Retroviruses, 4th Annual Conference." Washington, DC, January 22-26 (Abstract LB2).
24. Vacca JP, Dorsey BD, Schleif WA, Levin RB, McDaniel SL, Darke PL, Zugay J, Quintero JC, Blahy OM, Roth E, Sardana VV, Schlabach AJ, Graham PI, Condra JH, Gotlib L, Holloway MK, Lin L, Chen I-W, Vastag K, Ostovic D, Anderson PS, Emini EA and Huff JR (1994) L-735,524: An orally bioavailable HIV-1 protease inhibitor. Proc Natl Acad Sci USA 91: 4096-4100.
25. Wiklund B, Lijeqvist L and Rokaeus A (1984) Neurotensin increases net fluid secretion and transit rate in small intestine of man. Regul Pept 8:33-39.
26. Young SD, Britcher SF, Tran LO, Payne LS, Lumma WC, Lyle TA, Huff JR, Anderson PS, Olsen DB, Carrol SS, Pettibone DJ, O'Brien JA, Ball RG, Balani SK, Lin JH, Chen I-W, Schleif WA, Sardana VV, Long WJ, Bymes VW and Emini EA (1995) L-743,726 (DMP-266): A novel, highly potent non-nucleoside inhibitor of the human immunodeficiency virus type I reverse transcriptase. Antimicrob Agents Chemother 39:2602-2605.